Biggest pharma deal ever faces aging patents, tough politics
A record pharmaceutical deal between Bristol-Myers Squibb Co. and Celgene Corp. will face obstacles on several fronts, including expiring patents on Celgene's cornerstone drug, cri…
A record pharmaceutical deal between Bristol-Myers Squibb Co. and Celgene Corp. will face obstacles on several fronts, including expiring patents on Celgene's cornerstone drug, cri…